<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215462</url>
  </required_header>
  <id_info>
    <org_study_id>00-012</org_study_id>
    <nct_id>NCT00215462</nct_id>
  </id_info>
  <brief_title>Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma</brief_title>
  <official_title>A Phase II Study of Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect anti-tumor activity of vinorelbine when given to
      patients with esophageal or gastric tumors. We will also collect information on the
      toxicities of vinorelbine in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will receive vinorelbine intravenously once per week for eight weeks. These
           treatments will be repeated after the initial eight weeks as long as the patient
           continues to receive benefit from the treatment. If the patient experiences significant
           toxicities, the dose may be reduced or the chemotherapy may be discontinued.

        -  Before beginning treatment and during therapy, routine laboratory tests, scans and
           x-rays will be done to check the body's response to treatment. A physical exam will be
           done at the start of the study and before each course of treatment. Scans will be done
           after eight weeks of therapy.

        -  Patients will remain on this study as long as their disease does not become worse or
           they do not experience severe side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the anti-tumor activity of vinorelbine when administered to patients with locally advanced or metastatic esophageal or gastric adenocarcinoma.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the toxicities of vinorelbine in this patient population.</measure>
  </secondary_outcome>
  <enrollment>32</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Stomach Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally unresectable or metastatic esophageal adenocarcinoma. Locally unresectable or
             metastatic gastric adenocarcinoma. Only patients with measurable tumors are eligible.

          -  No more than one prior chemotherapy regimen

          -  ECOG performance status of 0-1

          -  Life expectancy of &gt; 12 weeks

          -  Greater than or equal to 1,200 calorie/day intake

          -  ANC &gt; 1,500/mm3

          -  AST &lt; 3 x ULN

          -  Total bilirubin &lt; 2.0 ng/dl

          -  Platelets &gt; 100,000/mm3

          -  Serum creatinine &lt; 2.0 mg/dl

        Exclusion Criteria:

          -  Prior therapy with vinca alkaloids

          -  Chemotherapy within the past three weeks

          -  Clinically apparent central nervous system metastases or carcinomatous meningitis

          -  Peripheral neuropathy &gt; 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Kulke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Matthew Kulke, MD</name_title>
    <organization>Dana-Farber Cancer Institute</organization>
  </responsible_party>
  <keyword>gastric adenocarcinoma</keyword>
  <keyword>esophageal adenocarcinoma</keyword>
  <keyword>vinorelbine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

